CBIO

Crescent Biopharma
$16.93
+$0.63 (+3.87%)Jul 27, 2026
2.0FairMoatMint rating

MoatMint rates Crescent Biopharma (CBIO) 2.0 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.4 out of 10.

Key metrics

The numbers that frame CBIO today
Market cap
$466.79M
P/E (TTM)
-2.9
EV / FCF
-3.7
Gross margin
100%
EV / Sales
25.7
ROIC
1,853.7%
Div yield
0%
Debt / equity
0.0
52wk Low
$8.72
52wk High
$27.41

CBIO stock rating

How CBIO scores on quality, value, growth, momentum and financial health
2.0out of 10
Fair overallFair business, expensive priceTop 80% of ~5,000 US stocks
QualityPoor0.4/10
GrowthNeutral4.9/10
MomentumGood7.1/10
ValuePoor0.9/10
Financial HealthFair2.5/10

Growth

Revenue and earnings trend for CBIO
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about CBIO
Is Crescent Biopharma a good buy?
No. Crescent Biopharma has strong momentum, but poor quality undercuts the setup. Growth looks mixed. The support signal is useful, but not decisive. We think Crescent Biopharma is selling at a very high price.
What is the market capitalization of CBIO?
Crescent Biopharma's market capitalization is $466.79M.
What is the P/E ratio for CBIO stock?
Crescent Biopharma's current P/E ratio is -2.9.
What is the 52-week high for CBIO stock?
The 52-week high for Crescent Biopharma is $27.41. The current close of $16.93 is 38.2% below that high.
What is the 52-week low for CBIO stock?
The 52-week low for Crescent Biopharma is $8.72. The current close of $16.93 is 94.2% above that low.
Does CBIO stock pay dividends?
Crescent Biopharma does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CBIO?
Crescent Biopharma's Debt / Equity ratio is 0.01.